Table 3 The list of DNA methyltransferase inhibitors and related TIME or tumor alter
DNMTi | Function | Combined use | Tumor | PMID |
|---|---|---|---|---|
Decitabine | Increased expression of cancer-testis antigens | – | Ovarian cancer | 26098711 |
Tumor cell lysis by CTL | PD-L1/PD-1 blocker | Rhabdomyosarcoma | 32528824 | |
Increased memory T cell infiltration and up-regulation CTLA-4 and FOXP3 | ipilimumab | Melatoma | 36706355 | |
CTL-mediated tumor cell killing | IFN-γ | Neuroblastoma | 21626030 | |
PD-1 blocking | Pembrolizumab | Leukemia | 35017151 | |
Increased B lymphocytes | CAR-T | Lymphoma | 36059523 | |
Enhance the secretion of ifn-γ and mage-a3 antigen-sive t cells | – | Esophageal squamous cell carcinoma | 30797153 | |
Upregulation the genes involved in congenital and adaptive immunity and PD-L1 | Nivolumab | NSCLC | 34140403 | |
Reverse the depletion of CD8+ TIL and improve T cell response | Nivolumab | gastric cancer | 35024441 | |
Azacytidine | Inducing apoptosis of p53-dependent cells | Nivolumab | squamous cell carcinoma of the head and neck | 28916527 |
Down-regulate B-cell lymphoma 2 | venetoclax | Acute myelogenous leukemia | 32054729 | |
Reduce the suppressive function of Tregs | – | Myelodysplastic syndrome | 23242597 | |
Upregulate the genes involved in congenital and adaptive immunity and PD-L1 | Nivolumab | NSCLC | 29195073 | |
Increased plasma HMGB1 expression | – | Osteosarcoma | 29097772 | |
Zebularine | Promote the infiltration of CD8 T cells and NK cells | – | Myeloma | 32394351 |
Hydralazine | Upregulate HLA-1 antigen expression and antigen-specific CTL response | Valproic acid | Cervical cancer | 17192185 |
Induce ICD and CTL infiltration | bortezomib | Pan-cancer | 36031455 | |
EGCG | Reduce TAM to inhibit tumor growth | Genistein | Pan-cancer | 31877341 |